Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10435791 | 0.79 | HPGD (0.54) | HPGDPOLBMEN1KMT2AMAPK1 | |
| SCHEMBL27600331 | 0.76 | CTSD (0.49) | HPGDPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL15033602 | 0.75 | NPC1 (0.67) | HPGDPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2216336 | 0.75 | LMNA (0.66) | HPGDMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL17442116 | 0.74 | HPGD (0.46) | HPGDPOLBMEN1KMT2AMAPK1 | |
| SCHEMBL7162161 | 0.73 | NPC1 (0.64) | HPGDPOLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL782110 | 0.72 | CTSD (0.73) | HPGDPOLBALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1577945 | 0.72 | SMN1; SMN2 (0.75) | HPGDPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL11423315 | 0.72 | GPR35 (0.47) | POLBMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL394290 | 0.72 | MEN1 (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103983627-A | Pyridopyrimidine compounds as anti-tubercular agents | PASTEUR INSTITUT KOREA | 2014-08-13 | — | — | CN | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| CN-102105470-B | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2014-06-04 | — | — | CN | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| CN-102105470-A | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2011-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | HPGD 1413/4885POLB 550/4885MEN1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.